Takeda launches narcolepsy drug after 15-year development effort

Key facts

• Orzeyful targets the root cause of narcolepsy, not just symptoms.
• Development of Orzeyful began around 15 years ago.
• The drug was developed at Takeda's Shonan Health Innovation Park in Fujisawa, Japan.

After approximately 15 years of development, Japan's Takeda Pharmaceutical has fully launched Orzeyful, a narcolepsy treatment that targets the root cause rather than addressing only the symptoms. The drugmaker started developing Orzeyful in what is now known as Shonan Health Innovation Park in Fujisawa, Japan.